Eli Lilly and Company, D-Wave Quantum, McKesson, AbbVie, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market prescription drugs and medical therapies. Investors in these equities gain exposure to industry-specific drivers such as clinical trial outcomes, regulatory approvals and patent lifecycles. Because drug development is costly and time-intensive, pharma stocks can be volatile, with share prices often swinging sharply on news of trial successes or setbacks. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE LLY traded down $6.28 during midday trading on Friday, reaching $745.17. The stock had a trading volume of 1,987,504 shares, compared to its average volume of 3,499,889. The company has a market capitalization of $706.22 billion, a price-to-earnings ratio of 63.64, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The stock has a 50-day moving average of $814.48 and a 200-day moving average of $812.71. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.
Read Our Latest Research Report on LLY
D-Wave Quantum (QBTS)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.
Shares of NYSE:QBTS traded up $0.55 during trading on Friday, hitting $10.97. 131,883,471 shares of the company's stock were exchanged, compared to its average volume of 36,242,821. The business's 50-day simple moving average is $7.29 and its 200 day simple moving average is $5.71. The company has a market cap of $3.20 billion, a price-to-earnings ratio of -26.12 and a beta of 0.90. D-Wave Quantum has a 52-week low of $0.75 and a 52-week high of $11.95.
Read Our Latest Research Report on QBTS
McKesson (MCK)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
MCK traded up $5.67 during trading on Friday, hitting $695.92. 1,252,469 shares of the company traded hands, compared to its average volume of 895,512. The company has a market cap of $87.22 billion, a PE ratio of 31.86, a P/E/G ratio of 1.29 and a beta of 0.53. McKesson has a 1 year low of $464.42 and a 1 year high of $728.48. The stock's 50-day simple moving average is $677.23 and its two-hundred day simple moving average is $618.78.
Read Our Latest Research Report on MCK
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of ABBV stock traded up $1.42 during trading hours on Friday, hitting $187.00. The stock had a trading volume of 4,617,487 shares, compared to its average volume of 6,100,475. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The stock has a market capitalization of $330.80 billion, a price-to-earnings ratio of 77.92, a PEG ratio of 1.62 and a beta of 0.56. AbbVie has a one year low of $153.58 and a one year high of $218.66. The stock's 50-day moving average price is $194.70 and its two-hundred day moving average price is $187.26.
Read Our Latest Research Report on ABBV
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of GILD traded down $1.72 during mid-day trading on Friday, hitting $96.44. 7,523,135 shares of the stock were exchanged, compared to its average volume of 7,572,183. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $120.08 billion, a PE ratio of 260.65, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $119.96. The firm has a 50-day moving average of $107.59 and a two-hundred day moving average of $99.17.
Read Our Latest Research Report on GILD
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
